Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dexlansoprazole - Takeda

Next Previous
Drug Profile

Dexlansoprazole - Takeda

Alternative Names: Dexilant; Dexivant; Kapidex™; T-168390; TAK-390; TAK-390 modified release; TAK-390MR; TAK-390MROD

Latest Information Update: 14 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Anti-inflammatories; Antiulcers; Gastric antisecretories; Pyridines; Small molecules; Sulfoxides
  • Mechanism of Action Antacids; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Erosive oesophagitis; Gastro-oesophageal reflux
  • No development reported Gastrointestinal disorders

Most Recent Events

  • 21 Jul 2026 Takeda completes a phase II trial for Gastro-oesophageal reflux (In children, In infants) in USA, Canada, Colombia, Belgium, Israel, Italy, Mexico, Poland, Portugal, Lithuania and Brazil (PO, Controlled-release) (NCT02616302)
  • 06 May 2026 Takeda terminates a phase-II trial in Erosive oesophagitis (In children) in Mexico, Lithuania, Colombia, Canada, USA (PO) due to study related reasons (NCT02615184) (EudraCT2014-004507-73)
  • 23 May 2023 Phase-II clinical trials in Erosive oesophagitis (In children) in Belgium, Portugal, Poland, Italy, Mexico, Lithuania, Colombia, Canada, USA (PO) (NCT02615184) (EudraCT2014-004507-73)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top